Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Galegenimab in Geographic Atrophy
NCT03295877Phase 1Completed
- Sponsor
- Genentech
- Start
- Sep 2017
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of galegenimab in geographic atrophy (GA) (2 arms), sponsored by Genentech. Primary endpoint: Rate of Adverse Events. Started Sep 2017; status: completed.
02
Drugs
galegenimab
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT03295877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03295877.